CN104974988A - 抗胰腺癌单克隆抗体及其应用 - Google Patents
抗胰腺癌单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN104974988A CN104974988A CN201510466976.2A CN201510466976A CN104974988A CN 104974988 A CN104974988 A CN 104974988A CN 201510466976 A CN201510466976 A CN 201510466976A CN 104974988 A CN104974988 A CN 104974988A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- pancreas
- pancreatic cancer
- application
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 47
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 45
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 42
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 25
- 230000002946 anti-pancreatic effect Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 claims abstract description 52
- 102000036639 antigens Human genes 0.000 claims abstract description 52
- 108091007433 antigens Proteins 0.000 claims abstract description 52
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 7
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000003745 diagnosis Methods 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 238000013399 early diagnosis Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000013115 immunohistochemical detection Methods 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 38
- 210000004027 cell Anatomy 0.000 abstract description 33
- 210000000496 pancreas Anatomy 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 229920001817 Agar Polymers 0.000 abstract description 11
- 239000008272 agar Substances 0.000 abstract description 11
- 230000012010 growth Effects 0.000 abstract description 7
- 238000011580 nude mouse model Methods 0.000 abstract description 7
- 238000004321 preservation Methods 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000002054 transplantation Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 28
- 238000000034 method Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000011470 radical surgery Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229940005654 nitrite ion Drugs 0.000 description 2
- 238000002262 pancreatoduodenectomy Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 206010061000 Benign pancreatic neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100029801 Calcium-transporting ATPase type 2C member 1 Human genes 0.000 description 1
- 108050001979 Calcium-transporting ATPase type 2C member 1 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000012106 cystic neoplasm Diseases 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 201000005221 pancreatic serous cystadenoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/067—Pancreatitis or colitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510466976.2A CN104974988B (zh) | 2015-07-31 | 2015-07-31 | 抗胰腺癌单克隆抗体及其应用 |
PCT/CN2016/091737 WO2017020752A1 (zh) | 2015-07-31 | 2016-07-26 | 抗胰腺癌单克隆抗体及其应用 |
US15/749,490 US10444237B2 (en) | 2015-07-31 | 2016-07-26 | Anti-pancreatic cancer monoclonal antibody and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510466976.2A CN104974988B (zh) | 2015-07-31 | 2015-07-31 | 抗胰腺癌单克隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104974988A true CN104974988A (zh) | 2015-10-14 |
CN104974988B CN104974988B (zh) | 2016-08-24 |
Family
ID=54271952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510466976.2A Active CN104974988B (zh) | 2015-07-31 | 2015-07-31 | 抗胰腺癌单克隆抗体及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10444237B2 (zh) |
CN (1) | CN104974988B (zh) |
WO (1) | WO2017020752A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017020752A1 (zh) * | 2015-07-31 | 2017-02-09 | 南京麦科林生物医药科技有限公司 | 抗胰腺癌单克隆抗体及其应用 |
CN112300283A (zh) * | 2019-07-29 | 2021-02-02 | 深圳华大生命科学研究院 | 一种抗人胰腺癌单克隆抗体及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144891A1 (en) * | 2007-05-30 | 2008-12-04 | F. Hoffmann-La Roche Ag | Humanized and chimeric anti-trop-2 antibodies that mediate cancer cell cytotoxicity |
CN102321173A (zh) * | 2011-08-12 | 2012-01-18 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2513308A1 (en) * | 2003-01-17 | 2004-08-05 | Josef Michl | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
CA2731438C (en) * | 2008-08-08 | 2017-07-11 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
AU2011207189B2 (en) * | 2008-08-08 | 2014-01-16 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
CN104974988B (zh) * | 2015-07-31 | 2016-08-24 | 南京麦科林生物医药科技有限公司 | 抗胰腺癌单克隆抗体及其应用 |
-
2015
- 2015-07-31 CN CN201510466976.2A patent/CN104974988B/zh active Active
-
2016
- 2016-07-26 WO PCT/CN2016/091737 patent/WO2017020752A1/zh active Application Filing
- 2016-07-26 US US15/749,490 patent/US10444237B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144891A1 (en) * | 2007-05-30 | 2008-12-04 | F. Hoffmann-La Roche Ag | Humanized and chimeric anti-trop-2 antibodies that mediate cancer cell cytotoxicity |
CN102321173A (zh) * | 2011-08-12 | 2012-01-18 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
Non-Patent Citations (2)
Title |
---|
KOJI HIRAYAMA, M.D.等: "Characterization and Biodistribution of a Mouse/Human Chimeric Antibody Directed against Pancreatic Cancer Mucin", 《CANCER》 * |
袁玫等: "抗胰腺癌单克隆抗体PS-10的制备特性及用于诊断的初步研究", 《免疫学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017020752A1 (zh) * | 2015-07-31 | 2017-02-09 | 南京麦科林生物医药科技有限公司 | 抗胰腺癌单克隆抗体及其应用 |
CN112300283A (zh) * | 2019-07-29 | 2021-02-02 | 深圳华大生命科学研究院 | 一种抗人胰腺癌单克隆抗体及其制备方法和应用 |
CN112300283B (zh) * | 2019-07-29 | 2024-01-02 | 深圳华大生命科学研究院 | 一种抗人胰腺癌单克隆抗体及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
US10444237B2 (en) | 2019-10-15 |
WO2017020752A1 (zh) | 2017-02-09 |
US20180224457A1 (en) | 2018-08-09 |
CN104974988B (zh) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6240112B2 (ja) | 腫瘍細胞由来微小胞 | |
UA120166C2 (uk) | Антитіло, що специфічно зв'язується з folr1, та спосіб виявлення рецептора фолієвої кислоти 1 | |
CN101570575B (zh) | Sncg的单克隆抗体及其应用 | |
CN102507943B (zh) | 一种用于检测非小细胞肺癌的双抗体夹心elisa试剂盒及其制备方法 | |
CN103923212A (zh) | Ehd2抗体及其在制备乳腺癌免疫组化检测试剂中的应用 | |
CN104974988B (zh) | 抗胰腺癌单克隆抗体及其应用 | |
CN101302254B (zh) | 抗肝癌源性生长因子单克隆抗体及其应用 | |
CN105353132B (zh) | non B‑s IgG作为干/祖细胞标志物的应用 | |
CN103555668B (zh) | 杂交瘤细胞株及其产生的抗Wnt5a单克隆抗体与应用 | |
Xu et al. | Preclinical evaluation of Mab CC188 for ovarian cancer imaging | |
CN107144695A (zh) | Arl13b蛋白在癌症诊断中的应用 | |
CN104894073B (zh) | 杂交瘤细胞株Zj/2D8及其检测尼克酰胺‑N‑甲基化酶抗原的应用 | |
CN101514230B (zh) | Ard1的单克隆抗体及其应用 | |
CN105462935B (zh) | 抗卵巢癌单克隆抗体及其应用 | |
CN103130896B (zh) | 抗细胞表面异位表达的单克隆抗体及其制备方法和用途 | |
CN104945496A (zh) | 一种多肽及其在制备与纯化对ehd2特异的抗体中的应用 | |
CN104945506A (zh) | 一种用于乳腺癌诊断和预后判断的免疫组化试剂 | |
CN102297971A (zh) | 一种检测癌或恶性肿瘤组织中jwa表达的试剂盒 | |
CN105753984B (zh) | 一种早期筛查实体瘤或癌症的酶联免疫检测试剂盒及应用 | |
Sharma | Inhibition of CD146 in breast cancer stem cells and tumorigenesis to control breast cancer metastasis | |
Liu et al. | Talin1 promotes HCC progression by regulating NRG1/PI3K/AKT axis | |
Okui et al. | The prognosis-based classification model in resectable pancreatic cancer | |
CN100567323C (zh) | 睾丸特异性蛋白50单克隆抗体、多克隆抗体的制备及用途 | |
CN102532317B (zh) | Pes1的单克隆抗体及其应用 | |
CN102234631B (zh) | 一种人泛素偶联酶UbcH10单克隆抗体杂交瘤DY03及单克隆抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151014 Assignee: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. Assignor: Nanjing Renchen Biotechnology Co.,Ltd. Contract record no.: 2015320000650 Denomination of invention: Anti-pancreatic cancer monoclonal antibody and application thereof License type: Common License Record date: 20151218 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160727 Address after: Spark Road 210032 Jiangsu province Nanjing city high tech Development Zone No. 10 Dingye biotech building block D Room 308 Applicant after: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. Address before: 210032, Jiangsu Province, Pukou District, Nanjing hi tech Development Zone, 10 Spark Road, ding industry, 100 Thai biological building, block D, room 306 Applicant before: Nanjing Renchen Biotechnology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151014 Assignee: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. Assignor: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. Contract record no.: 2017320000069 Denomination of invention: Anti-pancreatic cancer monoclonal antibody and application thereof Granted publication date: 20160824 License type: Common License Record date: 20170310 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180403 Address after: 210032 room No. 307, block D, No. 10, Batai bio building, No. 10, Xing fire road, Jiangbei new area, Jiangsu Patentee after: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. Address before: Spark Road 210032 Jiangsu province Nanjing city high tech Development Zone No. 10 Dingye biotech building block D Room 308 Patentee before: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230310 Address after: Room 308, Block D, Dingye Baitai Biological Building, No. 10 Xinghuo Road, Nanjing High-tech Zone, Jiangsu Province Patentee after: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. Address before: Room 307, Block D, Dingye Baitai Biological Building, No. 10 Xinghuo Road, Jiangbei New District, Nanjing City, Jiangsu Province Patentee before: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. |